Abstract
Phototherapy is an important treatment for pigmentary problems, in particular, for vitiligo, which is a common acquired depigmenting skin disease. PUVA therapy, both topical and systemic, has been a mainstay of treatment for years. However, PUVA is associated with an increase in skin malignancies especially with high cumulative sessions of phototherapy. In recent years, NBUVB and the excimer laser/lamp have become increasingly used as the main treatment modalities for vitiligo. The efficacy, relative ease of administration and lower skin carcinogenic risk have made these treatments the phototherapy treatment of choice. NBUVB is widely used for full body phototherapy, but targeted NBUVB devices are also available. Phototherapy with home hand-held phototherapy units has also been shown to have good efficacy with better adherence to treatment. The excimer laser and lamp emit UV light at wavelength of 308 nm and deliver targeted phototherapy. The phototherapy modalities can be combined with other modalities of treatment such as topical calcineurin inhibitors and calcipotriol for greater efficacy. Phototherapy still remains an important, safe and effective treatment for vitiligo.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ceoviae R, Pasiae A, Lipozenciase J, Jakiae-Razumoviae J, Szirovicza L, Kostoviae K. Antiproliferative, antiangiogenic, and apoptotic effect of photochemotherapy (PUVA) in psoriasis. Coll Anthropol. 2007;31:551–6.
Falabella R, Barona MI. Update on skin repigmentation therapies in vitiligo. Pigment Cell Melanoma Res. 2008;22:42–65.
Wu CS, Lan CC, Wang LF, Chen GS, Wu CS, Yu HS. Effects of psoralen plus ultraviolet A irradiation on cultured epidermal cells in and patients with psoriasis in vivo. Br J Dermatol. 2007;156:122–9.
Ibbotson SH, Farr PM. The time-course of psoralen ultraviolet A (PUVA) erythema. J Invest Dermatol. 1999;113:346–50.
Kwok YK, Anstey AV, Hawk JL. Psoralen photochemotherapy (PUVA) is only moderately effective in widespread vitiligo: a 10-year retrospective study. Clin Exp Dermatol. 2002;27(2):104–10.
Tallab T, Joharji H, Bahamdan K, Karkashan E, Mourad M, Ibrahim K. Response of vitiligo to PUVA therapy in Saudi patients. Int J Dermatol. 2005;44(7):556–8.
Singh S, Khandpur S, Sharma VK, et al. Comparison of efficacy and side-effect profile of oral PUVA vs. oral PUVA sol in the treatment of vitiligo: a 36 week prospective study. J Eur Acad Dermatol Venereol. 2013;27(11):1344–51.
Esmat SM, El-Tawdy AM, Hafez GA, et al. Acral lesions of vitiligo: why are they resistant to photochemotherapy. J Eur Acad Dermatol. 2012;26(9):1097–104.
El Mofty M, Bosseila M, Mashaly HM, Gawdat H, Makaly H. Broadband ultraviolet A vs psoralen in the treatment of vitiligo: a randomized controlled trial. Clin Exp Dermatol. 2013;38(8):830–5.
Parsad D, Saini R, Verma N. Combination of PUVAsol and topical calcipotriol in vitiligo. Dermatology. 1998;197(2):167–70.
Handa S, Pandhi R, Kaur I. Vitiligo: a retrospective comparative analysis of treatment modalities in 500 patients. J Dermatol. 2001;28:461–6.
Halpern SM, Anstey AV, Dawe RS, et al. Guidelines for topical PUVA: a report of a workshop of the British Photodermatology group. Br J Dermatol. 2000;142:22–31.
Valkova S, Trashlieva M, Christova P. Treatment of vitiligo with local khellin and UVA: comparison with systemic PUVA. Clin Exp Dermatol. 2004;29(2):180–4.
Ortel B, Tanew A, Honigsmann H. Treatment of vitiligo with khellin and ultraviolet A. J Am Acad Dermatol. 1998;90(5):720–4.
Duschet P, Schwartz T, Pusch M, Gschnait F. Marked increase of liver transaminases after Khellin and UVA therapy. J Am Acad Dermatol. 1989;21(3 Pt 1):592–4.
Morison WL, Marwaha S, Beck L. PUVA-induced phototoxicity: incidence and causes. J Am Acad Dermatol. 1997;36:183–5.
Ledbetter LS, Hsu S. Melanonychia associated with PUVA therapy. J Am Acad Dermatol. 2003;4:S31–2.
Pathak MA, Mosher DB, Fitzpatrick TB. Safety and therapeutic effectiveness of 8 methoxy-psoralen4,5′,8-trimethlypsoralen, and psoralen in vitiligo. Natl Cancer Inst Monogr. 1984;66:165–73.
Stern RS, Laird N, Melski J, Parrish JA, Fitzpatrik TB, Bleich NL. Cutaneous squamous cell carcinoma in patients treated with oral methoxsalen photochemotherapy for psoriasis. N Engl J Med. 1984;310:1156–61.
Nijsten TE, Stern RS. The increase risk of skin cancer is persistent after discontinuation of psoralen + ultraviolet A: a cohort study. J Invest Dermatol. 2003;121:252–8.
Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxalen (psoralen) and ultraviolet A radiation (PUVA): the PUVA follow-up study. N England J Med. 1997;336:1041–5.
Goekerman WH. The treatment of psoriasis. Northwest Med. 1925;24:229–31.
Fischer T. Comparative treatment of psoriasis with UV-light, trioxsalen plus UV-light, and coal tar plus UV-light. Acta Derm Venereol. 1977;57:345–50.
Bandow GD, Koo JY. Narrow-band ultraviolet B radiation: a review of the current literature. Int J Dermatol. 2004;43:555–61.
Anderson RR, Parrish JA. The optics of human skin. J Invest Dermatol. 1981;77:13–9.
el-Ghorr AA, Norval M. Biological effects of narrow-band (311 nm TL01) UVB irradiation: a review. J Photochem Photobiol B. 1997;38:99–106.
Kao CH, Yu HS. Depletion and repopulation of Langerhans cells in nonsegmental type vitiligo. J Dermatol. 1990;17:287–96.
Staricco RG, Miller-Milinska A. Activation of the amelanotic melanocytes in the outer root sheath of the hair follicle following ultra violet rays exposure. J Invest Dermatol. 1962;39:163–4.
Cui J, Shen LY, Wang GC. Role of hair follicles in the repigmentation of vitiligo. J Invest Dermatol. 1991;97:410–6.
Wu CS, Lan CC, Yu HS. Narrow-band UVB irradiation stimulates the migration and functional development of vitiligo-IgG antibodies-treated pigment cells. J Eur Acad Dermatol Venereol. 2012;26:456–64.
Westerhof W, Nieuweboer-Krobotova L. Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. Arch Dermatol. 1997;133:1525–8.
Scherschun L, Kim JJ, Lim HW. Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo. J Am Acad Dermatol. 2001;44:999–1003.
Hamzavi I, Jain H, McLean D, et al. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol. 2004;140:677–83.
Natta R, Somsak T, Wisuttida T, et al. Narrowband ultraviolet B radiation therapy for recalcitrant vitiligo in Asians. J Am Acad Dermatol. 2003;49:473–6.
Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol. 2000;42:245–53.
Kanwar AJ, Dogra S. Narrow-band UVB for the treatment of generalized vitiligo in children. Clin Exp Dermatol. 2005;30:332–6.
Yones SS, Palmer RA, Garibaldinos TM, et al. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs narrowband-UV-B therapy. Arch Dermatol. 2007;143:578–84.
Jekler J, Larkö O. Vitiligo treatment in childhood: a state of the art review. Pediatr Dermatol. 2010;27:437–45.
Casacci M, Thomas P, Pacifico A, et al. Comparison between 308-nm monochromatic excimer light and narrowband UVB phototherapy (311-313 nm) in the treatment of vitiligo – a multicentre controlled study. J Eur Acad Dermatol Venereol. 2007;21:956–63.
Verhaeghe E, Lodewick E, van Geel N, et al. Intrapatient comparison of 308-nm monochromatic excimer light and localized narrow-band UVB phototherapy in the treatment of vitiligo: a randomized controlled trial. Dermatology. 2011;223:343–8.
Lopes C, Trevisani VF, Melnik T. Efficacy and safety of 308-nm monochromatic excimer lamp versus other phototherapy devices for vitiligo: a systematic review with meta-analysis. Am J Clin Dermatol. 2016;17:23–32.
Wong R, Lin AN. Efficacy of topical calcineurin inhibitors in vitiligo. Int J Dermatol. 2013;52:491–6.
Majid I. Does topical tacrolimus ointment enhance the efficacy of narrowband ultraviolet B therapy in vitiligo? A left-right comparison study. Photodermatol Photoimmunol Photomed. 2010;26:230–4.
Esfandiarpour I, Ekhlasi A, Farajzadeh S, et al. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. J Dermatolog Treat. 2009;20:14–8.
Goktas EO, Aydin F, Senturk N, et al. Combination of narrow band UVB and topical calcipotriol for the treatment of vitiligo. J Eur Acad Dermatol Venereol. 2006;20:553–7.
Leone G, Pacifico A, Iacovelli P, et al. Tacalcitol and narrow-band phototherapy in patients with vitiligo. Clin Exp Dermatol. 2006;31:200–5.
Ada S, Sahin S, Boztepe G, et al. No additional effect of topical calcipotriol on narrow-band UVB phototherapy in patients with generalized vitiligo. Photodermatol Photoimmunol Photomed. 2005;21:79–83.
Arca E, Taştan HB, Erbil AH, et al. Narrow-band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo. J Dermatol. 2006;33:338–43.
Khullar G, Kanwar AJ, Singh S, et al. Comparison of efficacy and safety profile of topical calcipotriol ointment in combination with NB-UVB vs. NB-UVB alone in the treatment of vitiligo: a 24-week prospective right-left comparative clinical trial. J Eur Acad Dermatol Venereol. 2015;29:925–32.
Westerhof W, d’Ischia M. Vitiligo puzzle: the pieces fall in place. Pigment Cell Res. 2007;20:345–59.
Choudhry SZ, Bhatia N, Ceilley R, et al. Role of oral Polypodium leucotomos extract in dermatologic diseases: a review of the literature. J Drugs Dermatol. 2014;13:148–53.
Middelkamp-Hup MA, Bos JD, Rius-Diaz F, et al. Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study. J Eur Acad Dermatol Venereol. 2007;21:942–50.
Winkelmann RR, Del Rosso J, Rigel DS. Polypodium leucotomos extract: a status report on clinical efficacy and safety. J Drugs Dermatol. 2015;14:254–61.
Elgoweini M, Nour El Din N. Response of vitiligo to narrowband ultraviolet B and oral antioxidants. J Clin Pharmacol. 2009;49:852–5.
Dell’Anna ML, Mastrofrancesco A, Sala R, et al. Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial. Clin Exp Dermatol. 2007;32:631–6.
Thody AJ. Alpha-MSH and the regulation of melanocyte function. Ann N Y Acad Sci. 1999;885:217–29.
Fabrikant J, Touloei K, Brown SM. A review and update on melanocyte stimulating hormone therapy: afamelanotide. J Drugs Dermatol. 2013;12:775–9.
Lim HW, Grimes PE, Agbai O, et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol. 2015;151:42–50.
Nicolaidou E, Antoniou C, Stratigos AJ, et al. Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. J Am Acad Dermatol. 2007;56:274–8.
Brazzelli V, Antoninetti M, Palazzini S, et al. Critical evaluation of the variants influencing the clinical response of vitiligo: study of 60 cases treated with ultraviolet B narrow-band phototherapy. J Eur Acad Dermatol Venereol. 2007;21:1369–74.
Hallaji Z, Ghiasi M, Eisazadeh A, et al. Evaluation of the effect of disease duration in generalized vitiligo on its clinical response to narrowband ultraviolet B phototherapy. Photodermatol Photoimmunol Photomed. 2012;28:115–9.
Sitek JC, Loeb M, Ronnevig JR. Narrowband UVB therapy for vitiligo: does the repigmentation last? J Eur Acad Dermatol Venereol. 2007;21:891–6.
Guillet G, Helenon R, Gauthier Y, et al. Progressive macular hypomelanosis of the trunk: primary acquired hypopigmentation. J Cutan Pathol. 1988;15:286–9.
Relyveld GN, Menke HE, Westerhof W. Progressive macular hypomelanosis: an overview. Am J Clin Dermatol. 2007;8:13–9.
Santos JB, Almeida OL, Silva LM, et al. Efficacy of topical combination of benzoyl peroxide 5% and clindamycin 1% for the treatment of progressive macular hypomelanosis: a randomized, double-blind, placebo-controlled trial. An Bras Dermatol. 2011;86:50–4.
Thng ST, Long VS, Chuah SY, et al. Efficacy and relapse rates of different treatment modalities for progressive macular hypomelanosis. Indian J Dermatol Venereol Leprol. 2016;82:673–6.
Sim JH, Lee DJ, Lee JS, et al. Comparison of the clinical efficacy of NBUVB and NBUVB with benzoyl peroxide/clindamycin in progressive macular hypomelanosis. J Eur Acad Dermatol Venereol. 2011;25:1318–23.
Kim MB, Kim GW, Cho HH, et al. Narrowband UVB treatment of progressive macular hypomelanosis. J Am Acad Dermatol. 2012;66:598–605.
Duarte I, Nina BI, Gordiano MC, et al. Progressive macular hypomelanosis: an epidemiological study and therapeutic response to phototherapy. An Bras Dermatol. 2010;85:621–4.
Bilsland D, Dawe RS. Ultraviolet phototherapy and photochemotherapy of skin disease. In: Ferguson J, Dover JS, editors. Photodermatology. London: Manson Publishing Ltd; 1996. p. 113–24.
Zanolli MD, Feldman SR. Phototherapy treatment protocols for psoriasis and other phototherapy-responsive dermatoses. New York: Taylor & Francis Group; 2004.
Madigan LM, Al-Jamal M, Hamzavi I. Exploring the gaps in the evidence-based application of narrowband UVB for the treatment of vitiligo. Photodermatol Photoimmunol Photomed. 2016;32:66–80.
Kist JM, Van Voorhees AS. Narrowband ultraviolet B therapy for psoriasis and other skin disorders. Adv Dermatol. 2005;21:235–50.
Hexsel CL, Mahmoud BH, Mitchell D, et al. A clinical trial and molecular study of photoadaptation in vitiligo. Br J Dermatol. 2009;160:534–9.
Schneider LA, Hinrichs R, Scharffetter-Kochanek K. Phototherapy and photochemotherapy. Clin Dermatol. 2008;26:464–76.
Ibbotson SH, Bilsland D, Cox NH, et al. An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report. Br J Dermatol. 2004;151:283–97.
de Gruijl FR, Rebel H. Early events in UV carcinogenesis – DNA damage, target cells and mutant p53 foci. Photochem Photobiol. 2008;84:382–7.
Cooper SJ, Bowden GT. Ultraviolet B regulation of transcription factor families: roles of nuclear factor-kappa B (NF-kappaB) and activator protein-1 (AP-1) in UVB-induced skin carcinogenesis. Curr Cancer Drug Targets. 2007;7:325–34.
Bishop DT, Demenais F, Iles MM, et al. Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet. 2009;41:920–5.
Jin Y, Birlea SA, Fain PR, et al. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med. 2010;362:1686–97.
Teulings HE, Overkamp M, Ceylan E, et al. Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners. Br J Dermatol. 2013;168:162–71.
Paradisi A, Tabolli S, Didona B, et al. Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo. J Am Acad Dermatol. 2014;71:1110–6.
Shan X, Wang C, Tian H, Yang B, Zhang F. Narrow-band ultraviolet B home phototherapy for vitiligo. Indian J Dermatol Venereol Lepro. 2014;80(4):336–8.
Tien Guan ST, Theng C, Chang A. Randomized, parallel group trial comparing home-based phototherapy with institution-based 308 excimer lamp for the treatment of focal vitiligo vulgaris. J Am Acad Dermatol. 2015;72(4):733–73.
Baltas E, Csoma Z, Ignacz F, et al. Treatment of vitiligo with the 308-nm xenon chloride excimer laser. Arch Dermatol. 2002;138:1619–20.
Hadi SM, Spencer JM, Lebwohl M. Treatment of vitiligo using the 308-nm excimer laser for the treatment of vitiligo. Dermatol Surg. 2004;30(7):983–6.
Hadi S, Tinio P, Al-Ghaithi K, Al-Quari H, Al-Helalat M, Lebwohl M, Spencer J. Treatment of vitiligo using the 308nm excimer laser. Photomed Laser Surg. 2006;24:354–7.
Zhang XY, He LY, Dong J, et al. Clinical efficacy of the 308-nm excimer laser in the treatment of vitiligo. Photodermatol Photoimmunol Photomed. 2010;26:138–42.
Hofer A, Hassan AS, Legat FJ, et al. The efficacy of excimer laser (308 nm) for vitiligo at different body sites. J Eur Acad Dermatol Venereol. 2006;20:558–64.
Al-Otaibi SR, Zadeh VB, Al-Abdulrazzaq AH, et al. Using a 308-nm excimer laser to treat vitiligo in Asians. Acta Dermatovenereol Alp Panonica Adriat. 2009;18(1):13–9.
Fa Y, Lin Y, Chi WH, et al. Treatment of vitiligo with 308-nm excimer laser: our experience from a 2 year follow-up of 979 Chinese patients. J Eur Acad Dermatol Venereol. 2017;31(2):337–40.
Le Duff F, Fontas E, Giacchero D, et al. 308 excimer lamp vs 308-nm excimer laser for treating vitiligo: a randomized study. Br J Dermatol. 2010;163:188–92.
Shi Q, Li K, Fu J, Wang Y, Ma C, Li Q, Li C, Gao T. Comparison of the 308-nm ecimer laser with the 308-nm excimer lamp in the treatment of vitiligo – a randomized bilateral comparison study. Photodermatol Photoimmunol Photomed. 2013;29(1):27–33.
Lopes C, Trevisanni VF, Melnik T. Efficacy and safety of 308-nm monochromatic Excimer lamp versus other phototherapy devices for vitiligo: a systemic review and meta-analysis. Am J Dermatol. 2016;17(1):23–32.
Kawalek AZ, Spencer JM, Phelps RG. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg. 2004;30(2Pt1):130–5.
Passeron T, Ostovari N, Zakaria W, Fontas E, Larrouv JC, Lacour JP, Ortonne JP. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol. 2004;140(9):1065–9.
Nistico S, Chiricozzi A, Saraceno R, Schipani C, Chimenti S. Vitiligo treatment with monochromatic excimer light and tacrolimus: results of an open randomized controlled study. Photomed Laser Surg. 2012;30(1):26–30.
Matin M, Latifi S, Zoufan N, Koushki D, Mirhafari Daryasari SA, Rahdari F. The effectiveness of excimer laser on vitiligo treatment in comparison with a combination therapy of Excimer laser and tacrolimus in an Iranian population. J Cosmet Laser Ther. 2014;16(5):241–5.
Park OJ, Park GH, Choi JR, Jung HJ, ES O, Choi JH, Lee MW, Chang SE. A combination of excimer laser treatment and topical tacrolimus is more effective in treating vitiligo than either therapy alone for the initial 6 months, but not thereafter. Clin Exp Dermatol. 2016;41(3):236–41.
Hui-Lan Y, Xiao-Yan H, Jian-Yong F, Zong-Rong L. Combination of 308-nm excimer laser with topical pimecrolimus for the treatment of childhood vitiligo. Paediatr Dermatol. 2009;26(3):354–6.
Bae JM, Hong BY, Lee JH, Lee JH, Kim GM. The efficacy of 308-nm excimer laser/light (EL) and topical agent combination therapy versus EL monotherapy for vitiligo: a systematic review and meta-analysis of randomized controlled trials (RCTs). J Am Acad Dermatol. 2016;74(5):907–15.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Colin Theng, T.S., Tan, E.ST. (2018). Phototherapy in Pigmentary Disorders. In: Kumarasinghe, P. (eds) Pigmentary Skin Disorders. Updates in Clinical Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-319-70419-7_16
Download citation
DOI: https://doi.org/10.1007/978-3-319-70419-7_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-70418-0
Online ISBN: 978-3-319-70419-7
eBook Packages: MedicineMedicine (R0)